NeoGenomics, Inc. (NEO) Financial Statements
NeoGenomics, Inc. (NEO) reported trailing twelve-month revenue of $766.3M (up 11.2% year on year) and net income of -$51.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$7.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26. Results for the next quarter were released 5 Oct; these figures move once the 10-Q is filed.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.28 | 0.41 | 0.44 | 0.48 | 0.51 | 0.59 | 0.66 | 0.73 | 0.77 | |
| Gross profit | 0.13 | 0.20 | 0.19 | 0.19 | 0.19 | 0.24 | 0.29 | 0.31 | 0.34 | |
| Research & development | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | |
| Operating income | 0.01 | 0.01 | -0.01 | -0.12 | -0.16 | -0.11 | -0.09 | -0.12 | -0.07 | |
| Pre-tax income | 0.00 | 0.00 | -0.01 | -0.02 | -0.16 | -0.10 | -0.08 | -0.11 | -0.05 | |
| Income tax | 0.00 | -0.00 | -0.02 | -0.01 | -0.02 | -0.01 | -0.00 | -0.00 | -0.00 | |
| Net income | 0.00 | 0.01 | 0.00 | -0.01 | -0.14 | -0.09 | -0.08 | -0.11 | -0.05 | |
| Diluted EPS ($) | 0.07 | 0.08 | 0.04 | -0.07 | -1.16 | -0.70 | -0.62 | -0.84 | -0.40 | |
| Diluted shares (bn) | 0.092 | 0.104 | 0.112 | 0.120 | 0.124 | 0.126 | 0.127 | 0.128 | — |
USD billions · SEC XBRL
NeoGenomics, Inc. — questions
- What is NeoGenomics, Inc.'s revenue?
- $766.3M over the twelve months to 2026-06-30, up 11.2% year on year, from its 10-Q and 10-K filings.
- What is NeoGenomics, Inc.'s net income?
- -$51.9M over the twelve months to 2026-06-30.
- What is NeoGenomics, Inc.'s free cash flow?
- -$7.4M over the twelve months to 2026-06-30.
- What are NeoGenomics, Inc.'s diluted earnings per share?
- $-0.40 over the twelve months to 2026-06-30.
Every figure on this page comes from NeoGenomics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.